Taken together with the in vivo Aldefluor assay results, these findings suggest that the DSF/Cu complex, rather than DSF alone, targets ALDH-positive NSCLC stem cells with high potency and inhibits tumor recurrence in vivo. The gene discussed is LDHA; the disease is non-small cell lung carcinoma.